Selected References:
- Caballero Bermejo A, et al. 2020. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial. Trials; 21(1):794. PMID: 32938496 PMCID: PMC7492787 DOI: 10.1186/s13063-020-04633-3
- Khiali S, et al. 2021. A comprehensive review on sarilumab in COVID-19
- Affiliations expand. Expert Opin Biol Ther; 21(5):615-626. PMID: 33161757 DOI: 10.1080/14712598.2021.1847269
- Garcia-Vicuña R, et al. 2020. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials; 21(1):772. PMID: 32907638 PMCID: PMC7480631 DOI: 10.1186/s13063-020-04588-5
- No authors listed, 2020. Sarilumab. In: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–.PMID: 29999974 Bookshelf ID: NBK500915. https://www.ncbi.nlm.nih.gov/books/NBK500915/ Accessed 01/2022.
- Prieto-Peña D, et al. 2021. Biologic agents and small-molecule inhibitors in systemic autoimmune conditions: an update. Pol Arch Intern Med; 131(2):171-181. PMID: 32550671 DOI: 10.20452/pamw.15438
